|Bid||50.20 x 800|
|Ask||0.00 x 800|
|Day's Range||50.69 - 52.05|
|52 Week Range||49.92 - 69.13|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||12.56|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||2.28 (4.39%)|
|1y Target Est||58.72|
HENDERSONVILLE, TN / ACCESSWIRE / August 19, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, reminds investors that another purchaser ...
The recent market drop has certainly been brutal and quite broad. But then again, this bear move is opening up interesting opportunities.Just look at the cannabis space. In fact, the downturn of marijuana stocks preceded the recent decline of the overall markets, as various public cannabis companies had a tough time meeting investors' lofty expectations.In yesterday's trading, Canopy Growth (NYSE:CGC) was, at one point, off 10.5% to $28.60 (the stock was over $50 a few months ago). That was after the stock had dropped 6.6% the day before. And on Wednesday, Tilray (NASDAQ:TLRY) dove 15%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe declines were kind of scary. But when it comes to investing, going against the grain can mean getting strong returns.One marijuana stock that should get attention is Hexo (NYSE:HEXO). Since late April, Hexo stock price has gone from $8.30 to $4.47.But HEXO has a number of positive characteristics. First of all, HEXO has gotten validation from Molson Coors (NYSE:TAP), which has formed a partnership with the cannabis company. The focus of the deal is developing a line of cannabis-infused beverages that will hit the market on Dec. 16th ( when such drinks will be legalized in Canada).All in all, the deal should provide Hexo stock with a nice catalyst. TAP will leverage its extensive marketing and logistical capabilities on behalf of HEXO's products. TAP's creative skills should help HEXO develop compelling products. The partnership really does look like a win-win.This is what the CEO of Molson Coors of Canada, Frederic Landtmeters, had to say about the deal: "We look forward to partnering with HEXO, a recognized leader in the medical cannabis space in Canada that will bring robust production capacity, a track record of innovation, and, most importantly, shared values when it comes to doing business the right way and earning the trust of consumers."But ultimately this is about more than just Canada. Because of the U.S. Farm bill, Hexo will be able to launch CBD-based drinks in eight states next year. Key AdvantagesThe TAP deal illustrates a main benefit of HEXO: the company's high production output. Note that it has about 30% of the Quebec market.Another critical factor is that HEXO acquired Newstrike Brands Ltd for $197 million. As a result of the deal, Hexo boosted its annual capacity by about 150,000 kilograms.Now it's true that Hexo stock is not without its issues. The company's last earnings report was a major disappointment. It revenue came in at 13.02 million CAD, representing a quarter-over-quarter drop of about 9%. while the Street was looking for $14.8 million.But the cannabis industry is still in the early stages, so choppy results are normal. Then again, the industry's fundamentals remain bright. That is why companies like TAP, Altria (NYSE:MO) and Constellation Brands (NYSE:STZ) have invested billions in the category. The Bottom Line on Hexo StockWhen it comes to the cannabis space, I think the key is to focus on the dominant players. Size will certainly be essential, given the competitive environment. And HEXO looks well-positioned to perform well over the long-haul.Yet the volatility of Hexo stock price will likely remain high. That is why it's a good idea to take moderate positions - or dollar-cost average - to help mute the wide swings of HEXO stock.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post Is Hexo Stock a Falling Knife Or Has It Reached a Good Entry Point? appeared first on InvestorPlace.
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Molson Coors Brewing Company filed a derivative complaint against the company's directors and officers for breach of fiduciary duties.
From Canopy Growth Corp. (NYSE: CGC) and Constellation Brands (NYSE: STZ) to HEXO Corp. (NYSE: HEXO) and Molson Coors Brewing Co. (NYSE: TAP), cannabis companies have taken advantage of strategic partnerships with beer-makers in an effort to completely transform the cannabis-infusion game. The newest addition to this feat is an authentic mashup of two Michigan-based companies, making exciting waves in the newly regulated recreational market.
Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (LCI), Molson Coors Brewing Company (TAP), AxoGen, Inc. (AXGN), and American Renal Associates Holdings, Inc. (ARA) on behalf of long-term stockholders. Bragar Eagel and Squire is investigating certain officers and directors of Lannett Company, Inc. following a class action complaint that was filed against Lannett on November 16, 2016.
There's no way to possibly buy every pot stock on the market; there are just too many of them to choose from. Therefore, you'll need to narrow your focus, and Canada is truly the epicenter of activity when it comes to legalized cannabis. While everyone else is focusing on well-known brands like Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB), I believe that Hexo (NYSE:HEXO) stock is a terrific way to build a position in Canadian cannabis.Source: Shutterstock Of course, not everybody agrees with me on this point -- what else is new? Critics are quick to point out that Hexo has run into a bit of potential controversy recently, which I will address momentarily. * 15 Growth Stocks to Buy for the Long Haul In any case, I'm always open to debate and never afraid of controversy, so let's open up this big can of worms and talk about exactly why I'm leaning bullish on Hexo stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Big Cannabis Meets Big BeerEver since the U.S. government eased restrictions on hemp with the passage of the Farm Bill in December, I knew that large corporations would want to plant their flags in the cannabis market. Molson Coors (NYSE:TAP) was quick to move into the legalized cannabis space with a joint venture to sell pot-enhanced beverages with none other than -- you guessed it -- Hexo Corp.Interestingly, although Molson Coors is known as a beer manufacturer, the cannabis-infused beverages reportedly won't contain alcohol. I actually view this as a smart move, as the cannabis crowd and the beer crowd aren't necessarily the same people (though I'm sure there's some overlap there). In any case, the joint venture will be called Truss and these drinks are slated to begin selling on Dec. 16 of this year (the day when it's legal to consume these beverages in Canada, assuming regulators don't create any delays).Jay McMillan, the vice president of strategic development at Hexo, believes that the company is fully prepared for the Truss product launch:We'll have a very large supply so we'll be in a good position to be able to meet the demand of the marketplace and at the same time also ensure that we're meeting the variety that the marketplace wants.Mr. McMillan also said that Truss is looking into rolling out a CBD-enhanced drink in eight U.S. states by the year 2020. I feel that these products are the future of cannabis and will bolster the Hexo stock price in the long term; even if the naysayers can't see it now, they'll jump on the bandwagon after the HEXO share price is much higher than it is today. Don't Let the Controversy Stop You from Owning HEXO StockAmazingly, HEXO controls around 30% of the cannabis market in Quebec, a region which is projected to represent 20% or so of the Canadian market for marijuana. Of course, Hexo's partnership with Molson Coors could provide access to markets far beyond Quebec, so it's hard for me to imagine what the critics and short-sellers think will to happen to the HEXO stock price in the long term.Perhaps they're bearish because Hexo has run ads on Snap (NYSE:SNAP)'s Snapchat app. The ads contained cannabis-related content, thereby potentially running afoul of Health Canada's advertising guidelines. However, as Megan Henderson, the director of marketing and business development for HelloMD points out, there's a lot of gray area in Health Canada's guidelines.Hexo's Snapchat ads aren't any more controversial than similar ads run by Canopy Growth or Aphria (NYSE:APHA). Henderson feels that Health Canada isn't likely to mete out any severe punishment to Hexo (or Snap for that matter), and I tend to concur with that stance on the matter. The Takeaway on Hexo StockBring on the controversy, I say -- as well as the CBD-enhanced beverage revenues, as Hexo stock is a rock-solid entry point into the fascinating world of legalized Canadian cannabis.As of this writing, David Moadel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post Stake Your Claim in Canadian Cannabis with Hexo Stock appeared first on InvestorPlace.
Investors shaken by the stock market's pullback in August should be on the alert for even steeper declines ahead for six stocks with a range of vulnerabilities, including PayPal Holdings Inc. (PYPL), Dropbox Inc. (DBX), Molson Coors Brewing Company (TAP), MSG Network Inc. (MSGN), Domino’s Pizza Inc. (DPZ), and Dish Network Corp. (DISH). For its part, MSG Network's big challenge is loss of subscribers.
A Keystone Beer Contest 2019 gives participants the chance to win free rent for a year.Source: Shutterstock Here's what to know about Molson Coors' (NYSE:TAP) Keystone Beer Contest 2019. * You must be a legal resident of the U.S. and age 21 or older to take part. * The contest includes a total of 13 grand prizes, which is the free rent for a year reward. * Each of these grand prizes comes in the form of a check for $12,000. * Breaking that down means that winners will have $1,000 per month to pay their rent with. * To enter the contest, participants must submit their email address, address, name, phone number and date of birth. * They also need a keyword to be able to take part in the Keystone Beer Contest 2019. * There is a list of keywords available to users in a link right under the entry field for them. * Participants can submit an entry once per day. * There are also 166 first prizes that will be available to participants. * This comes in the form of what Keystone calls the "adulting transition pack." * That includes an inflatable chair, a shower curtain, a Hawaiian shirt and a chandelier made from Keystone Light cans. * The drawing for the contest will take place on Sept. 30, 2019. * It will have the company selecting five grand prize winners and 11 first prize winners from the all eligible entries in the National Pool. * The company will then select the remaining winners from Keyword Pools. * 7 Safe Dividend Stocks for Investors to Buy Right Now You can follow this link to sign up for the Keystone Beer Contest 2019 and learn more about the sweepstakes.InvestorPlace - Stock Market News, Stock Advice & Trading Tips More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Real Estate Investments to Ride Out the Current Storm * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk * 7 Safe Dividend Stocks for Investors to Buy Right Now As of this writing, William White did not hold a position in any of the aforementioned securities.The post Keystone Beer Contest 2019: How to Win Free Rent for a Year appeared first on InvestorPlace.
About a month ago, I wrote my first piece on newly public Canadian cannabis producer HEXO (NYSE:HEXO). I wrote that HEXO stock is interesting because the company is in the cannabis market, which is a non-cyclical growth sector. But I contended that HEXO stock wasn't compelling because HEXO had not yet proven that it was a good company.So I simply recommended that investors monitor HEXO stock but refrain from buying it. * 7 Safe Dividend Stocks for Investors to Buy Right Now Ever since my initial column was published, HEXO stock price has been exceptionally volatile. First, it dropped from $5 to $4 in just over a week. Then, it showed strong support at $4, and subsequently rebounded to $4.75.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNow I'm doubling down on my initial thesis. There are a lot of marijuana stocks out there. Most of them won't make it. Probabilities and fundamentals suggest that HEXO will be one of the companies that won't survive. Until that changes, long-term investors should stay away from HEXO stock. HEXO Is a Fine CompanyAt its core, HEXO is a fine company in a really good sector.For all intents and purposes, HEXO looks just like many other Canadian cannabis companies. HEXO grows, distributes, and sells medical and recreational cannabis, mostly in Canada, although it also exports cannabis to many other countries. The company, which has ample growing capacity, is focused on lowering its production costs and is excited about the upcoming legalization of cannabis vapes and edibles in Canada in late 2019.HEXO also has a unique partnership with Molson Coors (NYSE:TAP) which focuses on creating cannabis-infused, non-alcoholic beverages.All in all, HEXO is very similar to Tilray (NASDAQ:TLRY), Cronos (NASDAQ:CRON). Aphria (NYSE:APHA), and most of the other cannabis producers.But that's not a bad thing. All of these companies are competing for the global cannabis crown, which will one day be worth a ton. The global tobacco and alcoholic beverage markets each generate several hundred billion dollars of revenue annually and support several companies with annual top lines of $50 billion-plus.The cannabis industry will one day reach a similar size, and, like the alcohol and tobacco sectors, it will eventually support several $50 billion-plus companies. HEXO could be one of those companies some day, but that scenario probably won't materialize. The Long Term Outlook of HEXO Stock Is UncertainThe reality is that there are a lot of cannabis companies today, and, as I mentioned earlier, most of them won't survive. As the market matures, it will consolidate around a few large players, as the global tobacco and alcoholic beverage markets did. After this consolidation occurs, a few marijuana stocks will be big winners, and the rest of the names will fall by the wayside.The internet industry went through a similar process. Marijuana stocks in 2019 feel very similar to dot-com stocks back in 1999. Today, everyone is convinced that cannabis will become the next big thing, just as everyone was convinced back in 1999 that the internet was going to become the next big thing.The masses were right back in 1999, since today the internet is everywhere. But, between 1999 and 2019, a lot of dot-com stocks disappeared. Only a few titans, like Amazon (NASDAQ:AMZN) and Alphabet (NASDAQ:GOOG), became winners over the long-term.In other words, back in 1999, there were a lot of dot-com stocks. Most of them didn't make it to 2019. Only a few did. The few that did turned into huge winners. But an equally-weighted portfolio of dot com stocks assembled back in 1999 would've produced awful returns.Thus, when picking pot stocks in 2019, it's important to be selective. Don't expect every cannabis company to become a winner over the long-term. Most of them will be losers over the long-term.As a result, it's probably a good idea to only invest in cannabis companies that actually differentiate themselves by obtaining a large investment - see Canopy Growth (NYSE:CGC) - or with huge volumes and growth over the long-term, like Aurora (NYSE:ACB).Right now, HEXO has not yet meaningfully differentiated itself from the pack. This lack of differentiation is a reason to avoid HEXO stock for the foreseeable future. The Bottom Line on HEXO StockAt the risk of sounding like a broken record, I'll reiterate my thesis on HEXO stock.There are a lot of marijuana stocks out there. Most of them won't make it. So probabilities suggest that if you pick a random marijuana stock out of a hat, that marijuana stock won't produce good returns over the next decade. Because of that dynamic, investors have to be selective when picking pot stocks in 2019.In other words, they should only pick marijuana stocks of companies that have meaningfully differentiated themselves. HEXO has not done that. Consequently, investors should stay away from HEXO stock until the company finds a way to meaningfully differentiate itself.As of this writing, Luke Lango was long AMZN, GOOG, CGC, and ACB. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Real Estate Investments to Ride Out the Current Storm * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk * 7 Safe Dividend Stocks for Investors to Buy Right Now The post Why HEXO Stock Still Isn't a Compelling Investment appeared first on InvestorPlace.
REGINA, Saskatchewan, Aug. 13, 2019 -- Merchant Law Group LLP (www.merchantlaw.com) a national class action litigation firm, is investigating whether Molson Coors Canada Inc..
I've talked before about the possibility of the marijuana industry overtaking the alcohol industry. I've said that it could outpace cigarettes and tobacco, too.Source: Shutterstock But what if I told you that marijuana could also become a replacement for vegetables?It's true … but not quite in the way that it sounds. Let me explain.InvestorPlace - Stock Market News, Stock Advice & Trading TipsPrior to this year, cannabis in Canada could only be grown in indoor facilities such as greenhouses. But now, growers in that country are moving their operations outside. In June, Canopy Growth (NYSE:CGC), the biggest marijuana company on Earth, became the first to receive a license to cultivate in the great outdoors.Where are these companies planting their cannabis seeds? On land that previously grew … vegetables. It makes sense when you think about it.WeedMD (OTCMKTS:WDDMF), a licensed cannabis producer and distributor in Canada, recently said that it had planted 21,000 plants on 27 acres that were previously home to asparagus crops.Sorry moms out there, although I'm sure your children -- and some adults I know, too -- will be thrilled at the thought of a few less asparagus spears on their plates.Not to worry. Interest in marijuana is increasing around the world, and while I do expect cultivation to grow exponentially in the years ahead, I doubt it will have a major impact on your selection of vegetables.And while you're at the grocery store shopping for vegetables, you may want to keep an eye out for cannabis and CBD making their way into beverages. Arizona Beverage -- the company behind Arizona Tea -- signed a deal with Dixie Brands (OTCMKTS:DXBRF) to create a line of products that will begin with vape pens and gummies and eventually move into drinks like tea, lemonade, and sodas.This is a big move for Arizona, which is trying to get a step up on its competition. The line of products will be launched in the U.S. first before expanding to Canada and Latin America. Other businesses like Constellation Brands (NYSE:STZ) and Molson Coors Brewing Company (NYSE:TAP) are developing marijuana-infused beverages in Canada, but they're waiting for legalization in the United States before selling their products south of the border.As you know, I think marijuana legalization is coming a lot sooner than most people think. It all adds up to a huge opportunity to multiply your money many times over … much like what internet stocks offered in 1994 or Bitcoin offered in 2015. The cannabis industry is set to grow so much over the next decade that it will turn out to be one of the biggest investments opportunities of your life -- no matter when you were born. Knocking Out Opioids … LiterallyIn related news, Liz Carmouche -- who fought and lost to Ronda Rousey in the UFC's first female fight in November 2012 -- is preparing to square up against Valentina Shevchenko in the UFC's main event Saturday night.You may be wondering how cannabis and UFC (Ultimate Fight Club) go together. Carmouche is the connection.One of my researchers heard her speak at the World Cannabis Congress in New York City last year. Carmouche is anti-drug, but she is all for hemp-based CBD and uses various products. After trying CBD while training in California, she found that she had fewer negative side effects when managing pain than when taking aspirin. She said she believes CBD has huge upside potential as a replacement for opioids -- and I couldn't agree more.We definitely need something. According to the Centers for Disease Control, 130 people die in the United States every day because of opioids. And many turn from pills to heroin, causing those overdose rates to skyrocket.But how many people overdose on natural CBD? Zero. There aren't even any major side effects.The passage of the 2018 U.S. Farm Bill legalized industrial hemp, so expect to see more research and education into whether CBD could largely replace opioids across the country.That impact would be enormous. In 2016, the U.S. opioid market was valued at $23 billion. If even a portion of that shifts to alternatives in the next few years, most notably CBD, we're talking about billions of dollars… and the potential for investors to make 2X, 3X, 5X, and even 10X their money.Clearly, Carmouche's CBD regimen is working. She is the oldest fighter in her division at age 35 and more than four years older than Shevchenko. To quote the famous line from When Harry Met Sally, "I'll have what she's having!" In-Game Betting Makes it Into the NFLI love this time of year when football is back in season. I played it in college (after which I could have used some CBD-based pain medicine), and it remains my favorite sport to this day.Preseason started last night, and while exhibition games are mostly ho hum, this first one was worth paying attention to as live gaming made it into an NFL game for the first time.The Washington Redskins partnered with NBC Sports Washington to provide the league's first interactive, predictive-gaming telecast called "Predict the Game." It was the first attempt at in-game betting, which is going to be huge.Viewers who tuned into the game against the Cleveland Browns were able to bet on things like whether or not a team would score on its next possession, which player would make the most tackles, and which team would tally up the most rushing yards. It was free to play, and cash prizes of $1,000 were awarded each quarter.The sports betting industry hasn't taken off as quickly as I initially expected after it became up to individual states whether to make it legal. But I am as bullish as ever on the long-term outlook for sports betting stocks. This was a first attempt at it, and I believe the way sports are viewed will ultimately change dramatically in the years ahead. It will all be related to the potential to place many different wagers during the game -- just like NBC's and the Redskin's "Predict the Game."One league source from the NFL had this to say about gambling on football: "The owners see this as the next horizon … They see this as the next biggest revenue stream after television contracts. They believe it will be worth billions to the league."I do, too. As well as every other league, not to mention casinos, betting apps and websites, and more. Sports betting isn't getting as much attention as a lot of other major trends at the moment, but I would put it right up there with the themes I mentioned in the 10X Innovation Summit that have the potential to return massive profits. Autonomy in the Big AppleSelf-driving cars have finally made their way into the Big Apple. You won't see autonomous vehicles amid the hustle and bustle of downtown streets and Times Square, but in a small, 300-acre space called the Brooklyn Navy Yard, New York City's first autonomous shuttle service has opened its doors.Optimus Ride, a Boston-based MIT spinoff with a familiarly clever name, offers six electric vehicles that run on a short 1.1-mile route between the entrance to the Navy Yard and the New York City Ferry dock. Each car seats two safety drivers and has room for up to four passengers.Of course, there are far larger scale self-driving tests taking place throughout the country. But this latest one in one of America's major hubs is a another step toward what I call Transportation 2.0.Transportation 2.0 has the ability to create a multi-trillion-dollar opportunity. This will lead to trillions of dollars in money sloshing around in the coming decades -- and that is an investment opportunity you do not want to miss. Now is the time to get in for the biggest profits.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Real Estate Investments to Ride Out the Current Storm * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk * 7 Safe Dividend Stocks for Investors to Buy Right Now The post An Unlikely Victim of the Cannabis Craze appeared first on InvestorPlace.
Today we are going to look at Molson Coors Brewing Company (NYSE:TAP) to see whether it might be an attractive...
The cannabis industry continues to deliver storylines, both negative and positive, that leave investors scratching their heads about which pot stocks to buy. One recent story has shined a light on Hexo (NYSE:HEXO), which could end up hurting Hexo stock holders. Source: Shutterstock Hexo, the largest company by market share in Quebec, Canada's second-largest province by population, is facing additional scrutiny after The Friendly Bear, a short-seller research firm released a report July 29 suggesting it was using aggressive promotion tactics on Snap Inc's (NYSE:SNAP) Snapchat in violation of Canada's strict advertising laws regarding minors. The Friendly Bear went as far as suggesting Hexo could be Canntrust 2.0, a reference to Toronto-based CannTrust (NYSE:CTST), who've been forced to cease cannabis sales while Health Canada decides whether to suspend or revoke its license as a result of an audit that found the company was growing pot in five unlicensed rooms at its Pelham, Ontario, grow-op. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Hexo Stock and RegulationsLet's be clear about one thing. Any advertising violations, which Hexo vehemently denies, are not the same thing as growing illegal pot. People could go to jail over the CannTrust issue. * 7 S&P 500 Dividend Stocks to Buy With Yields of at Least 3% "We're in uncharted territory," said Trina Fraser, a cannabis lawyer with Brazeau Seller Law, about the Health Canada probe. "The potential for people to go to jail certainly exists. The potential for significant fines to be levied certainly exists."Anyone who's invested in cigarette companies knows you don't go to jail for advertising violations. Until proven otherwise, Hexo's reputation is entirely intact, in my opinion. However, the incident should make investors question Hexo's valuation. Hexo Stock ValuationAs I write this, the Hexo stock price is $4.70, well below $10, the share price I predicted it would hit in my May article about the company. At its current price, it has a market cap of $1.14 billion. As InvestorPlace's Ian Bezek recently stated, Hexo is nowhere near generating the CAD$400 million ($302 million) in revenue it's projecting by the end of 2020; it's currently at an annual run rate of C$70 million.That would imply it's trading at 16.3 times sales. Not nearly as high as Beyond Meat (NASDAQ:BYND) at 59 times sales, but pricey nonetheless. However, consider these two points before dumping on Hexo's current valuation.First, the Motley Fool's Keith Speights wrote an excellent piece July 28, using a back-of-the-napkin calculation to determine Hexo's future valuation. Speights hypothesized that since the Canadian adult-use recreational marijuana market is projected to reach $5 billion by 2024, and Hexo has 30% market share in Quebec, a province that accounts for 21% of Canada's population, it should have 6.3% market share for the entire country. He then upped that to 7% to account for its market share outside of Quebec. I like the way he's worked backward from the total market estimate. While it might turn out to be lower than $5 billion, the odds of Hexo losing market share in Quebec is unlikely. So, that works out to revenue of $350 million by 2024, or 3.3 times sales based on its current valuation. That's the first floor on HEXO. The Molson Coors FloorThe second floor is the 50/50 joint venture with Molson Coors (NYSE:TAP).As I stated in July, the Truss partnership with Hexo is ready to go when the legalization of cannabis-infused drinks happens in October, and distribution rolls out in December after the required 60-day waiting period. "We'll have a very large supply so we'll be in a good position to be able to meet the demand of the marketplace and at the same time also ensure that we're meeting the variety that the marketplace wants," Hexo's VP of Strategic Development, Jay McMillan said in an interview at the World Cannabis Congress in Saint John, New Brunswick, in June. What's that worth to Hexo stock? I believe that cannabis-infused drinks, edibles and vape concentrates will be far more lucrative on a global basis than the dried flower. The revenues generated from Truss could be significantly higher than Hexo's dried flower sales. And that doesn't take into consideration the real possibility that Molson Coors could partner with Hexo in the U.S.So, I don't think it's out of line to suggest the drinks portion could be worth at least $175 million (half the $350 million estimate by 2024 for dried flower) to Hexo. Add that to the $350 million and you get a current valuation that's just 2.2 times sales. Does Molson Coors act as a floor on Hexo stock?I think it does. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 8 Dividend Aristocrat Stocks to Buy Now No Matter What * 7 Stocks to Buy to Ride the Vegan Wave * 4 Safe Stocks to Buy Amid Trade War Turbulence The post Molson Coors May Be the Only Thing Propping Up HEXO Stock appeared first on InvestorPlace.
NEW YORK, Aug. 08, 2019 -- Bragar Eagel & Squire is investigating certain officers and directors of Grubhub, Inc. (NYSE: GRUB), Molson Coors Brewing Company (NYSE: TAP),.
Molson Coors Brewing Company (TAP) is one of the world's largest beer companies, producing the highly-recognized Coors, Molson, Miller and Blue Moon brands as well as numerous local, craft and specialty beers, notes George Putnam, editor of The Turnaround Letter.
The marijuana market has created an appealing opportunity for risk-tolerant investors who are willing to wait out the near-term turbulence. However, while deciding to invest in the cannabis boom might seem like a no-brainer, choosing a winner in the space takes a bit more analysis. Recently, Canadian marijuana firm Hexo Corp (NYSE:HEXO) has gained a lot of attention and made many traders' short list.Source: Shutterstock Here's a look at the case for and against Hexo stock. Pro: Hexo Stock Is Seeing Market Share GrowthRight now, Hexo controls roughly 30% of Quebec's marijuana market. That figure is likely to remain constant or rise over the next few years as the firm currently has a multi-year supply agreement that will keep its position relatively stable. As Canada's recreational pot market grows and regulations ease, Quebec will likely represent about 20% of the nation's overall marijuana market, giving Hexo a huge growth runway. With those figures in mind, Hexo stock could eventually capture between 7%-10% of Canada's overall marijuana market.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy on the Trade War Dip On top of that, Hexo has the potential to grow outside of Canada as well. The firm partnered with Molson Coors Brewing (NYSE:TAP), which looks likely to provide a large international growth runway as the marijuana market around the world develops. Plus, Hexo CEO Sebastien St-Louis has been open about his plans to partner with big names across a variety of industries in order to drive growth for HEXO stock in the years ahead. Pro: Analyst RecommendationsOf the 14 analysts who cover Hexo stock, 10 recommend buying the stock, three say to hold and only one says it's time to sell. Bank of America Merrill Lynch analyst Christopher Cary said that although he is expecting the Canadian cannabis market to struggle this year and next, HEXO is still likely to outperform the market.Plus, HEXO is a common purchase among cannabis fund managers further suggesting that the company is a market-beating bet. Pro: It's on SaleAnother reason investors might be interested in considering the Canadian marijuana company is then fact that Hexo's stock price is trading more than 50% lower than its April highs. Hexo stock only recently gained notoriety as one of the top-tier marijuana investments when the firm left the NYSE American exchange and joined the New York Stock Exchange, putting it on the same playing field as other marijuana heavyweights like Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB).The industry as a whole has lost some of its momentum, and HEXO has found itself burdened by some controversy that further depressed its share price. However, if you're willing to wait out near-term volatility, HEXO looks relatively cheap making now a good time to take a position. Con: Still ExpensiveDespite the weakness that the marijuana sector has experienced recently, it's important to note that cannabis stocks are still expensive when you compare them to the rest of the market. According to Charles Schwab, Hexo shares trade at 44 times the company's sales, a sky-high multiple when you compare it to the healthcare sector's average of 2.21.Part of the reason for HEXO's elevated multiples is the fact that the industry has a lot of potential growth on the horizon, but that doesn't take away the risk that investors are taking on by buying in an already-hyped-up industry. As the old adage goes, what goes up must come down, and eventually the marijuana industry's multiples will have to come back down to earth. Con: Management UncertaintyAny time upper management walks away from a company, investors are going to question their reasoning. That's even more the case with a young company on the rise like Hexo. In July, co-founder Adam Miron announced his departure from his role as chief branding officer.Miron said he will remain a part of the company as a board member and that he was ready to move on now that the firm has become "and established company." Perhaps it means nothing, but Miron's decision to walk away certainly raises a few red flags from an investment standpoint. Con: Marijuana Market UncertaintyAny time you're buying into a young industry you have to take into account the uncertainty that comes with it. The marijuana industry is a young one with a lot of regulatory concerns. Navigating such a complicated regulatory environment requires cannabis companies to make decisions based on future policy predictions.For HEXO we've already seen that play out as the firm defended itself against critics who chastised it for advertising its products using social media. Bottom LineIf you're looking for a marijuana stock to add to your portfolio, Hexo stock isn't a bad pick. The firm looks likely to benefit from the rising tide in the marijuana industry, and management's efforts to secure big-name, cross-industry partnerships looks like a good way to create growth avenues in the future. There's likely to be a great deal of turbulence over the next few years, but those risks appear to be industry wide.As of this writing, Laura Hoy did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy on the Trade War Dip * The 5 Highest-Rated Dow Stocks Right Now * 4 Cybersecurity Stocks to Buy for Long-Term Gains The post Should You Buy Hexo Stock? 3 Pros, 3 Cons appeared first on InvestorPlace.
[Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Traffic stats don't lie: among investment categories, few have the draw of legal marijuana. And within this broad segment, companies specializing in cannabidiol, or CBD, have generated significant buzz. But what exactly is this three-letter acronym, and how can CBD stocks boost your returns?Let's start with basic definitions. Cannabidiol represents one of several cannabinoids, or chemical compounds found in the cannabis sativa plant. But unlike the most famous cannabinoid tetrahydrocannabinol (THC), CBD does not trigger any psychoactive effect. In other words, users can enjoy this compound's benefits without getting high.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis opens up profound opportunities for marijuana stocks that have exposure to CBD. First, since this compound inherently lends itself to medicinal use, it tends to be treated favorably by legislation. Most states allow CBD use for therapeutic purposes. Given political and public sentiment, it's not inconceivable that all states will eventually green-light cannabidiol.Second, CBD has the potential to help solve a huge societal problem. Turn on the news, and you'll eventually find stories about the raging opioid crisis. What is less reported is that pharmaceutical companies contributed to the problem with highly addictive painkillers. Since CBD is not physically addictive, it could be a viable replacement for many addictive opioids.Finally, the U.S. may be the leader of the free world, but it stymies itself with antiquated laws. Our neighbors to the north became the first G7 nation to legalize recreational weed, while we still classify cannabis as a Schedule I narcotic. But growing legal momentum, especially with CBD-based medication, suggests we're turning a corner. * 10 Stocks to Buy on the Trade War Dip In the meantime, here are four CBD stocks to consider adding to your portfolio: Tilray (TLRY)Source: Shutterstock It's confession time: I'm very disappointed with how Tilray (NASDAQ:TLRY) and other CBD stocks have performed this year. For TLRY stock, shares are down over 38% since January's opening price.That said, I think we have some encouraging news. First, TLRY stock popped up over 7% on Friday's session. More importantly, shares are finding strong support at the psychologically significant $40 level. Recall that in late May to early June, TLRY fell below that mark. Since then, however, shares have only briefly dropped below $40.That to me communicates that TLRY stock is ready for a comeback. Fundamentally, I believe the shift in sentiment is well justified. Recently, the company shipped a bulk package of CBD into the U.K. Not only did this represent a significant departure from the North American cannabis market, British demand is incredibly strong. For instance, patients in the U.K. have requested CBD prescriptions from their doctors as an alternative to typical pharmaceutical products.Plus, Tilray has a production facility in Portugal, where they have successfully distributed CBD to other European countries, including Croatia and Germany. That's a big plus, not only for TLRY stock but for other CBD stocks as well. Aurora Cannabis (ACB)Source: Shutterstock On paper, Aurora Cannabis (NYSE:ACB) is a winner. Year-to-date, stakeholders of ACB stock are sitting on a 29% profit. That's not bad at all, considering that the benchmark S&P 500 index is up only 18%.But like many other CBD stocks, Aurora Cannabis is only a winner of the first quarter. Since the end of March, ACB stock has shed an alarming 30%. Is there any hope for this once high-flying cannabis play?One of the big reasons why many investors dumped ACB stock is the financials. Although Aurora Cannabis has many potential catalysts in the pipeline, this is part of the problem: stakeholders must hang their thesis on the term potential.On the other hand, what's real in the here and now is cash burn. Like other fancied CBD stocks that are now suffering volatility, Aurora is in a race against time. Management must convince prospective buyers that they have the financial stability necessary to wait until their catalysts start turning. * 7 Stocks the Insiders Are Buying on Sale Admittedly, CBD stocks are a risky play. But similar to Tilray's narrative, multiple international markets are coming around to medicinal marijuana. With Aurora's dominating international presence, I believe you can trust ACB stock. Hexo (HEXO)Source: Shutterstock Most investors realize that marijuana stocks of all stripes are ridiculously volatile. But even with that understood caveat, Hexo (NYSE:HEXO) has truly taken shareholders on a wild ride.Between the opening volley of this year to the end of April, the Hexo stock price skyrocketed nearly 131%. But from the first of May, shares have plummeted nearly 44%. Earnings season wasn't too kind on marijuana stocks. Thus, questions about fiscal stability dogged the sector.But despite the ugliness, I think Hexo stock has serious potential. And I'm not just saying that. Recently, I put skin in this game by buying up a stake. Like other shareholders, I'm feeling the pain from this wild investment. Still, my encouragement to you (and to myself) is to hold on.For one thing, Hexo stock received a credibility boost when it moved over to the New York Stock Exchange. In every other sector, this is just a natural progression for a company on the rise. But for Hexo, it represents collective legitimacy that lifts other marijuana stocks.Further, growing mainstream acceptance of CBD stocks is crucial for this market to eventually tap into traditional forms of financing. It also encourages other non-CBD related companies to partner with names like Hexo. Charlotte's Web (CWBHF)Source: Shutterstock Most CBD stocks hail from Canada, which is absolutely no surprise. Since our northern neighbors beat us to the legalization punch, they should get the glory. But a few companies call the U.S. home, and one of them is Charlotte's Web (OTCMKTS:CWBHF). And while CHWBHF stock doesn't have the same pedigree as the other marijuana stocks on this list, it still carries weight.That's because Charlotte's Web scored a massive coup recently when it announced a deal with grocery market giant Kroger (NYSE:KR). Kroger has just started carrying Charlotte's Web products. Moreover, they will expand their CBD offerings to 1,350 stores covering 22 states. Obviously, this is a massive victory for both CWBHF stock and CBD stocks overall.I'm not just excited about the headlining print. If you look at the 22 states where Kroger will sell CBD, many of them are conservative. We're talking places like Arizona, Kentucky, Montana and Texas. If these states can accept a marijuana derivative, it shouldn't take much for the rest of the country to follow suit. * 7 Stocks to Sell Amid an Escalating Trade War This is also the reason why CWBHF stock has taken a massive leap in the markets. Although I don't like chasing shares near their all-time highs, I think Charlotte's Web is a worthy candidate.As of this writing, Josh Enomoto is long HEXO stock. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy on the Trade War Dip * The 5 Highest-Rated Dow Stocks Right Now * 4 Cybersecurity Stocks to Buy for Long-Term Gains The post 4 CBD Stocks to Buy for Mainstream Marijuana Profits appeared first on InvestorPlace.
NEW YORK, Aug. 07, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Molson Coors Brewing Company (NYSE: TAP) concerning possible breaches of.
Molson Coors Brewing Co (NYSE: TAP ) hit multi-year lows Wednesday after reporting second-quarter sales, gross profit and operating income below the Street's expectations. The company also unexpectedly ...
With a new chief executive waiting to take on the role, JPMorgan analysts think investors are looking forward to lots of changes at Molson Coors Brewing Co. in 2020. The beer company announced on Wednesday that Mark Hunter will retire, effective September 27, with Gavin Hattersley, currently the Chief Executive of the U.S. business unit MillerCoors, his successor. The company also announced a second-quarter earnings and revenue miss on Wednesday. "At this point we think the Street is more or less expecting some sort of reset in 2020 as Mr. Hattersley provides his initial three-year plan," wrote JPMorgan in a note. "While this has resonated with CPG investors recently in similar C-level transitions and typically has resulted in positive share price performance, we think there is some level of skepticism that reinvestment will be enough to get underlying trends moving in the right direction because of the off-trend domestic premium beer category in the US." JP Morgan rates Molson Coors stock neutral with a $58 price target, down from $63. UBS analysts are bullish, "convinced" that the portfolio of premium brands like Peroni and Blue Moon will drive growth. "We remain confident that Molson Coors can stabilize topline trends on more favorable weather, easier compares and continued growth in premium brands," analysts said. UBS rates Molson Coors stock buy with a $71 price target, down from $76. Molson Coors stock is down 2% in Thursday after closing Wednesday down 5.2%.Shares have fallen nearly 6% for the year to date while the S&P 500 index has gained 17.5% for the period.